Biogen Stock Holdings Boosted by Brevan Howard

Hedge fund increases stake in biotech company by 149% in third quarter

Mar. 16, 2026 at 8:53am

Got story updates? Submit your updates here. ›

Brevan Howard Capital Management LP increased its position in Biogen Inc. (NASDAQ:BIIB) by 149.0% during the third quarter, according to the company's recent 13F filing with the Securities & Exchange Commission. The firm now owns 33,511 shares of the biotechnology company's stock, valued at $4,694,000.

Why it matters

This move by Brevan Howard, a prominent global macro hedge fund, suggests the firm sees potential upside in Biogen's stock. As one of the world's largest independent global macro hedge fund managers, Brevan Howard's investment decisions are closely watched by the broader market.

The details

Brevan Howard Capital Management LP acquired an additional 20,055 shares of Biogen during the third quarter, bringing its total position to 33,511 shares. This represents a 149% increase in the firm's holdings of the biotechnology company's stock compared to the prior quarter.

  • Brevan Howard increased its Biogen stake during the third quarter of 2026.

The players

Brevan Howard Capital Management LP

A prominent global macro hedge fund that manages over $20 billion in assets.

Biogen Inc.

A multinational biotechnology company focused on developing therapies for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

The takeaway

Brevan Howard's significant increase in its Biogen holdings suggests the hedge fund sees potential upside in the biotech company's stock, which could signal growing investor confidence in Biogen's product pipeline and future prospects.